Recent HIV infections in bisexual and gay men in New South Wales (NSW) in Australia have declined by almost one-third following the trial of HIV prevention medication PrEP (Pre-Exposure Prophylaxis), according to research by the Kirby Institute published today in The Lancet HIV.
These reductions provide more evidence to support the large-scale, targeted provision of PrEP to prevent HIV transmission – currently under review for much of the UK in NHS trials.
The new research, funded by NSW Health, reports the findings from the NSW PrEP trial (called EPICNSW), which was launched in March 2016. When taken daily, PrEP prevents HIV negative people from acquiring the virus. The EPIC-NSW trial is the first completed study globally to measure the impact of PrEP on reducing HIV in a large population.
Professor Andrew Grulich from the Kirby Institute at UNSW Sydney led the trial and commented, “the speed of the decline we’ve seen in new HIV infections in gay and bisexual men is a world first. In the year following the trial, state-wide new HIV infections in this population decreased by one third, from 149 infections in the 12 months prior, to 102 in the 12 months after.
“These numbers are the lowest on record since HIV surveillance began in 1985,” said Professor Grulich. “Our research tells us that these reductions are a result of PrEP, implemented on a background of high and increasing HIV testing and treatment rates.”
The declines were highest among Australian-born gay and bisexual men (48.7%) and gay and bisexual men living in the ‘gay suburbs’ of Sydney (51.8%). “These communities had the highest uptake of PrEP, and in these populations, new HIV infections have halved since the trial began,” said Professor Grulich.
